Skip to content

International Delivery — £35 per Order

Home/Learn/Semaglutide
Back to Learn Hub
Peptide Guide

Semaglutide (GLP-1 Receptor Agonist)

Category: GLP-1 Agonists

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management. It mimics the natural GLP-1 hormone that the body produces after eating, triggering insulin release and reducing appetite. The compound gained widespread attention after clinical trials showed significant weight reduction in study participants.

This guide compiles key literature themes, handling context, and practical comparison points for research-focused evaluation.

By Maylene · Page updated

Overview

What sets semaglutide apart from earlier GLP-1 agonists is its extended half-life. Structural modifications, including an albumin-binding fatty acid chain, allow it to remain active in the body for roughly a week.

Discovery & Background

Novo Nordisk developed semaglutide through systematic modification of the native GLP-1 molecule. The company received FDA approval for the diabetes indication in 2017 and for chronic weight management in 2021. The STEP trial program, which enrolled thousands of participants across multiple countries, provided the clinical evidence base. These trials were among the largest ever conducted for a weight management compound.

Mechanism of Action

Semaglutide binds to GLP-1 receptors found throughout the body, primarily in the pancreas, gut, and brain. Its effects extend well beyond simple blood sugar control.

  • 1
    Binds to GLP-1 receptors in pancreatic beta cells, stimulating glucose-dependent insulin secretion
  • 2
    Acts on the hypothalamus to reduce appetite and increase feelings of fullness
  • 3
    Slows gastric emptying, prolonging the sensation of satiety after meals
  • 4
    Reduces glucagon secretion, lowering hepatic glucose output
  • 5
    May have direct effects on the cardiovascular system through GLP-1 receptors in cardiac tissue
  • 6
    Fatty acid modification enables albumin binding, extending the half-life to approximately 7 days

Research Benefits

The benefit areas below reflect commonly discussed research interests for this peptide.

Weight Management Research

STEP trials demonstrated average body weight reductions of 15-17% in participants over 68 weeks, the largest effect seen with any single pharmacological agent.

Glycemic Control

Clinical trials showed significant reductions in HbA1c levels, with many participants achieving target glucose levels.

Cardiovascular Research

The SELECT trial showed a 20% reduction in major adverse cardiovascular events in participants without diabetes.

Extended Duration

Weekly administration improves research protocol compliance compared to daily-dosed alternatives.

Reported Side Effects & Considerations

  • •Gastrointestinal effects are the most commonly reported (nausea, vomiting, diarrhea) in clinical trials
  • •Effects often decrease over time
  • •Rare cases of pancreatitis observed in clinical settings
  • •Not recommended for research involving subjects with a history of medullary thyroid carcinoma
  • •Potential for gallbladder-related events

Storage Guidelines

Temperature

2-8C refrigerated

Once Reconstituted

Use within 28 days

Shelf Life

24 months refrigerated in original packaging

Frequently Asked Questions

What is semaglutide?

Semaglutide is a GLP-1 receptor agonist, a synthetic analog of the human GLP-1 hormone. It was developed by Novo Nordisk and has been extensively studied in large-scale clinical trials.

How does semaglutide differ from other GLP-1 agonists?

Semaglutide has a significantly longer half-life (about 7 days) due to structural modifications including a fatty acid side chain that binds to albumin.

What were the major clinical trials for semaglutide?

The STEP program (weight management), SUSTAIN program (diabetes), and SELECT trial (cardiovascular outcomes) are the three major trial programs, collectively involving tens of thousands of participants.

How should semaglutide be stored?

Semaglutide should be stored refrigerated at 2-8C. It should not be frozen. Once in use, it should be used within 28 days.

Sources & evidence

Maylene research library

These papers describe the stated compounds and study models. They do not test or certify Maylene products. Animal or cell findings do not establish human benefit, and pharmaceutical trials do not validate research-only pens.

Editorial approach and corrections

Research Disclaimer

This guide is for educational and informational purposes only. All information is based on published scientific research and peer-reviewed literature. Peptides sold by Maylene are intended solely for laboratory research use and are not for human consumption. Consult healthcare professionals before making any health decisions.

The catalogue

There is no Semaglutide product in the current catalogue. This guide is background reading.

Browse All Peptides

Explore More Peptide Guides

Explore adjacent compounds to compare mechanisms, side-effect discussions, and study focus across related peptides.

Start Your Research Today

Compare current listings, labelled content and product documentation before ordering.

Products from Maylene are supplied strictly for laboratory and scientific research use only.

Shop Peptides